The automated manipulator connects treatment and point of use through controlled loading, unloading, movement and delivery operations. Depending on the selected route, it handles canisters, sterile tanks or treated materials and manages their interface with the isolator or filling line. Automation removes avoidable manual interventions precisely where exposure, repeated handling and open connections create the greatest vulnerability.

The process combines deep vacuum with controlled vH₂O₂ injection to remove trapped air and drive the sterilant through the Tyvek® sheet, lid and double header-bag configuration until it reaches the internal vial surfaces. Vacuum level, H₂O₂ concentration, pulse sequence and exposure time are optimized around the complete packaged load. Temperature control prevents condensation, while the final deep-vacuum aeration phase accelerates residual removal and supports a shorter, release-ready industrial cycle.

Sterile manufacturing must control microorganisms, bacterial endotoxins and particles. Sterilization addresses viable contamination but does not necessarily eliminate endotoxins and pyrogens from glassware and product-contact components entering aseptic production.

Continuous depyrogenation tunnels are optimized for standardized, high-volume flows. Multi-product facilities must also manage changing batches, formats and non-standard components, creating the need for a flexible batch approach.

Compatible reusable parts are packaged in bags or loaded into closed canisters before steam sterilization. The process is developed around the complete load configuration to govern air removal, steam penetration, condensate management and drying. Once treated, the selected packaging or transfer system preserves the sterile state during unloading, movement and introduction into the aseptic processing environment.

The rapid growth of biologics, nanoparticle-based medicines and Advanced Therapy Medicinal Products (ATMPs) is redefining the relationship between pharmaceutical formulations and primary packaging.
Interactions between proteins such as insulin, nanoparticles and container surfaces are well-recognised phenomena that can influence product stability, efficacy and patient safety. As these therapies become increasingly sensitive, material compatibility can no longer be considered an intrinsic property of the container alone.

When manufacturers seek to move away from EtO towards a method that reduces toxic-residue concerns and the potential burden on patients, workers and the environment, selecting an alternative sterilant is only the beginning.
This is particularly true for the low-temperature sterilization of RTU glass vials in their complete packaging configuration. The sterilant must pass through the outer transport box, multiple porous barriers and enclosed packaging interfaces before reaching the internal vial surfaces. The same structure must then release residual sterilant within an acceptable aeration time.

Tyvek® bags provide a sterile barrier while allowing steam penetration, but processing machine parts inside porous packaging — particularly in double-bag configurations — introduces challenges that cannot be managed by temperature alone.

Irregular geometries, different thermal masses, folds, overlapping surfaces and contact with the trays influence air removal, steam circulation and condensate evacuation. At the same time, rapid pressure changes can mechanically stress the bags, while poorly controlled depressurization can cool the load and make drying more difficult.